Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
By H. Lokhorst, T. Plesner, J. Laubach, H. Nahi, P. Gimsing, M. Hansson, M. Minnema, U. Lassen, J. Krejcik, A. Palumbo and 11 more. New England Journal of Medicine, 2015
1,029 citations recorded by the source corpus.
Subfields: Hematology, Oncology, Physiology
View Paper: https://www.semanticscholar.org/paper/c731f1036338cb22a95a42420cb4ccf650d6c359
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
Citations in the corpus
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “Daratumumab targeting CD38 has shown promise in relapsed, refractory multiple myeloma.(84) In a phase II trial, daratumumab as a single-agent was produced a response rate of approximately 30% in heavily pretreated patients.”
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, background): “Daratumumab is active in relapsed, refractory multiple myeloma.(83) In a phase II trial, daratumumab as a single-agent was produced a response rate of approximately 30% in heavily pretreated patients.”